Enhanced in vivo immunogenicity induced by an antibody to the IL-4 receptor-associated gp200-MR6 molecule

Scandinavian Journal of Immunology

Volumn 44, Issue 2, 1996, Pages 135-142

  Sivolapenko, G B ^a   Imami, N ^a   Larche M ^a   Epenetos, A A ^a   Ritter, M A ^a  

^a HAMMERSMITH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

GLYCOPROTEIN; HEMOGLOBIN; IMMUNOGLOBULIN G1; INTERLEUKIN 4; INTERLEUKIN 4 RECEPTOR; MONOCLONAL ANTIBODY; TUMOR ANTIGEN;

ANIMAL EXPERIMENT; ANTIGEN PRESENTING CELL; ARTICLE; HUMAN; HUMAN TISSUE; IMMUNE RESPONSE; IMMUNIZATION; IMMUNOGENICITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RABBIT;

EID: 0030017735     PISSN: 03009475     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-3083.1996.d01-292.x     Document Type: Article

References (38)

1. Bamias A, Epenetos AA. Monoclonal antibodies in oncology: in vivo targeting for immunoscintigraphy and therapy of human malignancies. In: Ritter MA, Ladyman HM, eds. Monoclonal Antibodies: Production, Engineering and Clinical Application. Cambridge: Cambridge University Press, 1995:222-46.
2. Courtenay-Luck NS, Epenetos AA, Moore R et al. Development of primary and secondary immune responses to mouse monoclonal antibodies used in the diagnosis and therapy of malignant neoplasms. Cancer Res 1986;46:6489-93.
3. Courtenay-Luck NS, Epenetos AA, Sivolapenko GB, Larché M, Barkans J, Ritter MA. Development of anti-idiotypic antibodies against tumour antigens and autoantigens in ovarian cancer patients treated intraperitoneally with mouse monoclonal antibodies. Lancet 1988;II:894-7.
4. Reichmann L, Clark M, Waldmann H, Winter G. Reshaping human antibodies for therapy. Nature 1988;322:323-7.
5. Bird RE, Hardman KD, Jacobson JW et al. Single-chain antigen-binding proteins. Science 1988;242:423-6.
6. Huston JS, Levinson D, Mudgett-Hunter M et al. Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli. Proc Natl Acad Sci 1988;85:5879-83.
7. McCafferty J, Griffiths AD, Winter G, Chiswell DJ. Phage antibodies: filamentous phage displaying antibody variable domains. Nature 1990;348:552-4.
8. Ranges GE, Sriram S, Cooper SM. Prevention of type II collagen-induced arthritis by in vivo treatment with anti-L3T4. J Exp Med 1985;162:1105-10.
9. Hafler DA, Ritz J, Schlossman SF, Weiner HL. Anti-CD4 and anti-CD2 monoclonal antibody infusions in subjects with multiple sclerosis. J Immunol 1988;141:131-8.
10. Gutstein NL, Seaman WE, Scott JH, Wofsy D. Induction of immune tolerance by administration of monoclonal antibody to L3T4. J Immunol 1986;137:1127-32.
11. Benjamin RJ, Waldmann H. Induction of tolerance by monoclonal antibody therapy. Nature 1986;320:449-51.
12. Isaacs JD. Monoclonal antibodies in rheumatology. In: Ritter MA, Ladyman HM, eds. Monoclonal Antibodies: Production, Engineering and Clinical Application. Cambridge: Cambridge University Press, 1995:403-28.
13. Parish NM, Cooke A. Experimental studies on in vivo immunosuppression. In: Ritter MA, Ladyman HM, eds. Monoclonal Antibodies: Production, Engineering and Clinical Application. Cambridge: Cambridge University Press, 1995:292-316.
14. Giral M, Dantal J, Cantarovich D et al. Monoclonal antibodies in transplantation: use as therapeutic agents in clinical organ transplantation. In: Ritter MA, Ladyman HM, eds. Monoclonal Antibodies: Production, Engineering and Clinical Application. Cambridge: Cambridge University Press, 1995:340-61.
15. Bostrom L, Ringden O. Monoclonal antibodies in transplantation: prophyllaxis and treatment of graft-versus-host disease after bone marrow transplantation. In: Ritter MA, Ladyman HM, eds. Monoclonal Antibodies: Production, Engineering and Clinical Application. Cambridge: Cambridge University Press, 1995:317-39.
16. DeMaagd RA, Mackenzie WA, Schuurman H-J et al. The human thymus microenvironment: heterogeneity detected by monoclonal anti-epithelial antibodies. Immunology 1985;54:745-54.
17. Al Jabaari B, Ladyman HM, Larché M, Sivolapenko GB, Epenetos AA, Ritter MA. Elevated expression of the interleukin 4 receptor in carcinoma: a target for immunotherapy? Br J Cancer 1989;59:910-14.
18. Mat I, Larché M, Melcher D, Ritter MA. Tumour-associated upregulation of the IL-4 receptor complex. Br J Cancer 1990; 62(suppl. X):96-8.
19. Mat IB, Moors N, Melcher D, Foxwell BMJ, Ritter MA. Differential expression of the MR6 antigen and c-erbB-2 protein in breast tumours. In: Lemoine N, Epenetos AA, eds. Mutant Oncogenes: Targets for Therapy. London: Chapman and Hall Medical, 1993:53-64.
20. Kaklamanis L, Gatter KC, Mortensen N, Harris AL. Interleukin-4 receptor and epidermal growth factor receptor expression in colorectal cancer. Br J Cancer 1992;66:712-16.
21. Tungekar MF, Turley H, Dunnill MS, Gatter KC, Ritter MA, Harris AL. Interleukin 4 receptor expression on human lung tumours and normal lung. Cancer Res 1991;51:261-4.
22. Tungekar MF, Gatter KC, Ritter MA. Bladder carcinomas and normal urothelium universally express gp200-MR6, a molecule functionally associated with the interleukin-4 receptor (CD124). Br J Cancer 1996; 73:429-32.
23. Larché M, Lamb JR, O'Hehir RE et al. Functional evidence for a monoclonal antibody that binds to the human IL-4 receptor. Immunology 1988;65:617-22.
24. Imami N, Larché M, Ritter MA. Inhibition of alloreactivity by MoAb MR6: differential effects on IL-2- and IL-4-producing human T cells. Int Immunol 1994;6:1575-84.
25. Imami N, Taylor-Fishwick DA, Foxwell BMJ, Ritter MA. Ligation of gp200-MR6 enhances IL-4 function in human B cells. Submitted to Int Immunol 1996.
26. Taylor Papadimitriou J, Peterson J, Arklie J, Burchell J, Ceriani R, Bodmer W. Monoclonal antibodies to epithelium-specific components of the human milk fat globule membrane: production and reaction with cells in culture. Int J Cancer 1981;28:17-21.
27. Travers P, Bodmer WF. Preparation and characterisation of monoclonal antibodies against placental alkaline phosphatase and other human trophoblast-associated determinants. Int J Cancer 1984;33:633-41.
28. Spurr NK, Durbin H, Sheer D, Parkar M, Bobrow L, Bodmer WF. Characterisation and chromosomal assignment of a human cell surface antigen defined by the monoclonal antibody AUA1. Int J Cancer 1986;38:631-6.
29. Larché M, Lamb JR, Ritter MA. A novel T-lymphocyte molecule that may function in the induction of self-tolerance and MHC-restriction within the human thymic microenvironment. Immunology 1988;64:101-5.
30. Laemmli UK. Cleavage of structural proteins during assembly of the head of bacteriophage T4. Nature 1970; 227: 680-5.
31. Towbin H, Staehelin T, Gordon J. Electrophoretic transfer of proteins from polyacrylamide gels to nitrocellulose sheets: procedure and some applications. Proc Natl Acad Sci 1979;76:4350-4.
32. Sivolapenko GB, Kanariou M, Edwards RJ, Epenetos AA, Ritter MA. Immunosuppression by immunoglobulin deaggregation is not effective in reducing the anti-xenogeneic immunoglobulin response: experimental and clinical studies. Br J Cancer 1989;60:511-16.
33. von Gaudecker B, Kendall MD, Ritter MA. Immuno-electron microscopy of the human thymic microenvironment. Microscopy Research and Technique 1996; in press.
34. Carayanniotis G, Barber BH. Adjuvant-free IgG responses induced with antigen coupled to antibodies against class II MHC. Nature 1987;327:59-61.
35. Carayanniotis G, Vizi E, Parker RJM, Hodges RS, Barber BH. Delivery of synthetic peptides by anti-class II MHC monoclonal antibodies induces specific adjuvant-free IgG responses in vivo. Molecular Immunol 1988;25:907-11.
36. Casten LA, Kaumaya P, Pierce SK. Enhanced T-cell responses to antigenic peptides targeted to B cell surface Ig, Ia or class I molecules. J Exp Med 1988;168:171-80.
37. Snider DP, Kaubisch A, Segal DM. Enhanced antigen immunogenicity induced by bispecific antibodies. J Exp Med 1990; 171:1957-63.
38. Mjaaland S, Fossum S. Modulation of imune responses with monoclonal antibodies. I. Effects on regional lymph node morphology and on anti-hapten responses to haptenized monoclonal antibodies. Eur J Immunol 1990;20:1457-61.